Form 8-K INTERPARFUMS INC For: Apr 21
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
|
|
(State or other jurisdiction of |
|
Commission |
|
(I.R.S. Employer |
(Address of Principal Executive Offices)
(Registrant’s Telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2 below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting Material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange |
|
|
|
|
|
|
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Conditions
Certain portions of our press release dated April 21, 2026, a copy of which is annexed hereto as Exhibit no. 99.1, are incorporated by reference herein, and are filed pursuant to this Item 2.02. They are as follows:
- The 1st, 2nd (consisting of a table), 4th, 5th, 7th, 9th through 11th full paragraphs relating to net sales for the first quarter ended March 31, 2026
- Portions of the 3rd, 6th, 8th and 12th paragraphs relating to net sales for the first quarter ended March 31, 2026
Item 7.01 Regulation FD Disclosure
Certain portions of our press release dated April 21, 2026, a copy of which is annexed hereto as Exhibit no. 99.1, are incorporated by reference herein, and are filed pursuant to this Item 7.01. They are as follows:
- Portion of the 3rd paragraph relating to cautious optimism of the future of fragrance portfolio
- Portion of the 6th paragraph relating to future Montblanc product launch in second half of 2026
- Portion of the 8th paragraph relating to potential future Lacoste sales and new product launches in 2026, 2027 and 2028
- Portion of the 12th paragraph relating to potential sales improvement and new product launches for Donna Karan/DKNY
- The 13th full paragraph relating to the 2026 business challenges relating to the war in the Middle East and the overall business strategy for 2027
- The 14th through 16th paragraphs relating to the date for the issuance of financial results and earnings conference call details
- The 19th paragraph relating to forward-looking information
- The balance of such press release not otherwise incorporated by reference in Item 2.02.
Item 9.01 Financial Statements and Exhibits.
| 99.1 | Our press release dated April 21, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused and authorized this report to be signed on its behalf by the undersigned.
Dated: April 21, 2026
|
|
Interparfums, Inc. |
|
|
|
|
|
|
|
By: |
/s/ Michel Atwood |
|
|
|
Michel Atwood, |
|
|
|
Chief Financial Officer |
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
- Don't Miss the Next HBAR: The Best Crypto Presale to Buy in 2026 Revealed
- MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share